Study of a new drug for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older
- Have advanced kidney cancer that cannot be surgically removed or has spread
- Have at least one measurable tumor that has not been treated yet
- Have not had any previous treatment for kidney cancer (except immunotherapy after surgery more than a year ago)
- Be in generally good health, able to perform daily activities without much help
- Have adequate blood, liver, heart, and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
Hear when a new Advanced Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.